Dermatological Daktarin 2% Cutaneous Solution For Fungi And Mycosis 30ml

Miconazole-based skin solution.

Therapeutic indications

Daktarin Dermatologico Cutaneous Solution is used in the treatment of skin or nail infections caused by dermatophytes or Candida possibly complicated by Gram-positive bacterial superinfections.

Dosage and posology

The drug should be taken according to the following doses and methods: the treatment should be continued daily and continuously at least up to a week after the symptoms disappear, and it can last from 2 to 6 weeks, depending on the type and extent of the infection. Wash the affected area and dry well. Treat not only the infected part, but also the area around it. Wash your hands thoroughly after each application to avoid transferring germs to other parts of the body or to other people. Generally, Daktarin Dermatologico powder or skin spray, powder with Daktarin Dermatologico cream are used in combination.

Daktarin Dermatologico solution is applied with the brush inserted into the bottle cap. 1-2 times a day brush the solution on the infected nail, all around it and, if possible, under it and let it dry. Once dry, the solution forms an occlusive film on the nail. Before the next application, it is necessary to clean the nail with acetone. If this procedure is not performed, the overlapping layers become too thick and Daktarin Dermatological Solution can no longer reach the nail.

Overdose

In general, excessive use of Daktarin Dermatologico can cause skin irritation which generally disappears with discontinuation of therapy.

In case of accidental ingestion: Daktarin Dermatologico is intended for local application and not for oral use. In case of accidental ingestion of large quantities of Dermatological Daktarin, use appropriate supportive therapy. Accidental ingestion of DAKATRIN DERMATOLOGICO cutaneous solution can cause gastric irritation; furthermore, since the cutaneous solution contains alcohol, it is necessary to consider the quantity of alcohol eventually ingested, especially in children. Daktarin Dermatological powder and skin spray, powder contain talc: the accidental inhalation of large quantities of the medicine can cause obstruction of the respiratory tract. Respiratory arrest can be treated with intense supportive therapy and oxygen. Endotracheal intubation, removal of obstructive material and assisted breathing are recommended if breathing is impaired.

Contraindications

• Hypersensitivity to the active substance or to any of the excipients
• Babies and children (up to 12 years).

Side effects

Undesirable effects from post-marketing spontaneous reports from around the world, organized according to the MedDRA classification, are listed below. Undesirable effects are classified according to frequency according to the following convention: very common ≥ 1/10 common ≥ 1/100 and <1/10 uncommon ≥ 1/1000 and <1/100 rare ≥ 1/10000 and <1 / 1000 very rare <1/10000, including isolated reports.

- Disorders of the immune system

• Very rare: anaphylactic reactions, hypersensitivity and angioneurotic edema

- Skin and subcutaneous tissue disorders

• Very rare: urticaria, contact dermatitis, rash, erythema, itching, burning sensation of the skin

- General disorders and administration site conditions

• Very rare: irritation or other reactions at the application site

Pregnancy and breastfeeding

Daktarin Dermatologico, applied topically, is minimally absorbed into the systemic circulation (bioavailability <1%). However, while there is no evidence of embryotoxicity or teratogenicity in animals, the potential risks of prescribing Dermatological Daktarin during pregnancy must be weighed against the potential therapeutic benefits.

Miconazole, applied topically, is minimally absorbed into the systemic circulation and it is not known whether miconazole is excreted in human milk. Caution is advised in the use of topical products containing miconazole during breastfeeding

Special warnings

If sensitization or irritation occurs, discontinue treatment and institute appropriate therapy. Avoid contact with eyes. Wash your hands carefully after each application, unless the treatment affects the hands themselves. As the cutaneous solution contains alcohol, avoid contact with open wounds and mucous membranes. In these cases, use Daktarin Dermatological cream. Daktarin Dermatological skin powder contains talc: avoid inhaling the powder which could cause irritation of the respiratory tract. It is advisable to apply the following hygienic measures to avoid the sources of infections or reinfections: - keep towels and underwear for personal use in order to avoid the infection of other people; regularly change clothing that comes into contact with the infected area to avoid re-infection. Daktarin Dermatologico does not stain the skin or clothing. Severe hypersensitivity reactions, including anaphylaxis and angioedema, have been reported during treatment with topical miconazole formulations. If a reaction due to hypersensitivity or irritation occurs, the treatment should be discontinued. Daktarin Dermatologico must not come into contact with the mucous membrane of the eyes.

Daktarin Dermatological Cutaneous Solution contains propylene glycol which may cause skin irritation. The solution also contains ethyl alcohol: avoid contact with open wounds and mucous membranes.

Expiry and retention

Check the expiration date indicated on the package. The expiry date indicated on the package refers to the product in intact packaging, correctly stored. Store at a temperature not exceeding 25 ° C.

Warning : do not use the medicine after the expiry date indicated on the package.

Composition

100 ml of Daktarin Dermatological solution contain:

Active principle

Miconazole 2 g.

Excipients

Acrylic resin (Carboset 525), polymerized acrylic resin (Carboset 515), propylene glycol, alcohol.